Bisolvon Elixir

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisolvon Elixir

Property Description
Active ingredient Bromhexine Hydrochloride
Form Oral Liquid (Elixir/Solution)
Pharmacological class Mucolytic, Expectorant
Common use Easing productive (chesty) cough
Origin Synthetic derivative (of Vasicine)

What Type of Medicine is Bisolvon Elixir? (Classification and Form)

Bisolvon Elixir is a pharmaceutical preparation classified as a mucolytic and expectorant agent, supplied as an oral liquid solution, making it suitable for both adults and pediatric populations. This medication is specifically designed to act as a mucoactive agent for managing congestion and symptoms associated with a productive cough. The active compound belongs to the pharmacological class of secretolytics, a classification recognized in pharmacological studies. The Elixir formulation, a clear, aqueous/hydroalcoholic base, is a specific dosage form often positioned for its ease of swallowing.

Composition and Origin: Is Bromhexine a Synthetic Compound? (Substance and Source)

The sole active ingredient in Bisolvon Elixir is Bromhexine Hydrochloride, which is utilized as a single active ingredient product. The compound Bromhexine is structurally and chemically derived from Vasicine, a naturally occurring alkaloid found in the plant Adhatoda vasica. This confirms the medicine's origin as a synthetic derivative designed to enhance the beneficial mucolytic properties observed in the natural substance. Being a single-agent treatment, it differs from combination products that often incorporate antitussives to suppress the cough reflex.

The General Purpose of This Mucoactive Agent (Core Benefit)

The general purpose of this mucoactive agent is to facilitate a more effective cough by chemically thinning and loosening thick mucus. The drug achieves this by targeting the viscosity of respiratory secretions and breaking down the complex mucopolysaccharide fibers. This agent reduces the viscosity of respiratory secretions, which aids in the clearance of thick phlegm from the lungs. This process offers targeted relief from the sensation of heaviness caused by congestion in the respiratory tract.

What side effects are possible with Bisolvon Elixir?

Possible Side Effects and Safety Information

Official regulatory documents classify possible side effects by the body system affected and how often they are reported in clinical use or post-marketing surveillance.


Frequency-Classified Adverse Reactions

Adverse reactions that have been documented include:

  • Uncommon (may affect up to 1 in 100 people):
    • Gastrointestinal disorders, including nausea, vomiting, diarrhoea, and upper abdominal pain.
  • Rare (may affect up to 1 in 1,000 people):
    • Hypersensitivity reactions, rash, and urticaria (hives).
  • Not Known (frequency cannot be estimated from the available data):
    • Severe allergic reactions (including anaphylactic shock, angioedema) and bronchospasm.
    • Severe Cutaneous Adverse Reactions (SCARs), including Erythema Multiforme, Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP).

Critical Safety Restrictions and Limitations

Treatment must be discontinued immediately if new skin or mucosal lesions, a progressive skin rash, or signs of severe allergic reaction develop.

Safety documents advise caution for specific patient groups:

  • Patients with a history of, or existing, peptic ulceration.
  • Patients with severe hepatic or renal impairment.

Use during pregnancy and breastfeeding is generally advised to be avoided as a precautionary measure due to limited safety data available in humans, although animal studies have not shown harmful effects. The product is contraindicated in patients with known hypersensitivity to the active substance or excipients, and in patients with rare hereditary problems of fructose intolerance.

Overdose and Emergency Response

The official regulatory documentation for Bisolvon Elixir (Bromhexine Hydrochloride) defines the overdose profile primarily around transient clinical manifestations following accidental massive ingestion. The observed effects are generally reported as mild and self-limiting, with no specific severe or life-threatening organ toxicity cited in official documents.

Documented Clinical Manifestations

The formally documented signs and symptoms are concentrated in the gastrointestinal system, including Nausea, Vomiting, Diarrhea, and upper abdominal pain. Other manifestations that have been reported are general distress symptoms such as Headache, Dizziness, restlessness, and increased sweating. These effects are considered transient and resolve with appropriate care.

Mandated Emergency Response

Official regulatory guidance mandates that an individual must seek medical advice immediately upon the suspicion of an overdose or the onset of any associated symptoms. This immediate action is necessary because regulatory labels explicitly state that no specific antidote is known for Bromhexine Hydrochloride.

Official Supportive Measures

Overdose management is officially described as supportive and symptomatic treatment, focused on managing the clinical signs and maintaining patient stability. In cases of massive, recent ingestion, official documents indicate that procedures such as gastric lavage and the administration of activated charcoal may be considered by medical professionals as part of the management strategy.

Therapeutic Uses of Bisolvon Elixir

What Bisolvon Elixir Treats: Main Uses and Benefits

Bisolvon Elixir is a medication commonly used to help with symptoms related to the production of thick and excessive respiratory mucus. It is utilized for the symptomatic management of viscid mucoid secretions.

This supportive therapy is applied in acute episodes and recurrent manifestations of bronchopulmonary conditions that involve persistent, thick phlegm. These include acute bronchitis, symptomatic episodes of the common cold or influenza, and the challenging secretions associated with chronic bronchitis and bronchiectasis.

The primary symptomatic benefit is helping to support the clearance of the chest. It is often applied in scenarios where additional management of discomfort is required, relevant in situations where the cough is ineffective and symptomatic assistance is needed.

“This medication is relevant for easing symptoms related to viscid phlegm, supporting a more manageable cough and helping to address the sensation of heaviness in the chest.”

By assisting with symptoms that interfere with daily comfort, this therapy contributes to improved comfort during periods of heightened symptoms by easing the overall symptom load and helping patients cope more steadily.


Quick Fact: Relief for Productive Cough

Quick Fact: This medication is relevant for managing Productive Cough (chesty cough) and Thick Phlegm (viscid secretions) and helps ease the physical burden of heavy secretions.

Regulatory References

  1. HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

Bisolvon Elixir (Bromhexine Hydrochloride) eligibility is strictly defined by official regulatory documentation. Contraindicated populations who must not use this medicine include individuals with known hypersensitivity to the active ingredient or any excipients in the formulation. The medicine is also contraindicated in children under two years of age across many jurisdictions due to safety concerns.

Use is typically permitted for adults, adolescents, and children aged two years and above. However, specific condition-based restrictions apply to other groups, necessitating caution. Patients with a history of gastric or duodenal ulcers should use the medicine conditionally. Caution is also required for patients with severe hepatic (liver) impairment or severe renal (kidney) impairment, as metabolism and clearance may be affected.

Regarding reproductive status, the medicine is generally not recommended during the first trimester of pregnancy as a precautionary measure due to limited human data. Similarly, use is not recommended while breastfeeding, based on the potential for Bromhexine to be excreted into breast milk.

What should I know about interactions with other medicines?

Official Interaction Profile

Regulatory documents indicate that there have been no reports of clinically relevant unfavourable interactions with other medicinal products for the active substance, Bromhexine Hydrochloride. The interaction profile is instead defined by a few specific modifications to drug exposure and certain excipient-related constraints.

Interaction Type Interacting Substance/Condition Documented Regulatory Outcome
Local Exposure Modification Amoxicillin, Erythromycin, Oxytetracycline (Antibiotics) The concentration of these antibiotics in the sputum and bronchopulmonary secretions is officially documented to be increased upon co-administration.
Systemic Exposure Modification Food Intake Concomitant food intake leads to a documented increase in the systemic plasma concentration of the active substance.
Metabolic Potential CYP 450 2C9 or 3A4 Substrates Regulatory statements note that relevant pharmacokinetic interactions with substrates of these metabolic enzymes are formally classified as unlikely.

Interaction-Related Restrictions and Considerations

The medicine's formulation includes the excipient Maltitol Liquid, which imposes an interaction-related restriction: its use is restricted in individuals with hereditary fructose intolerance. Furthermore, clearance of the active substance or its metabolites may be reduced in patients with severe hepatic impairment. No mandatory timing rules or separation requirements between doses of this medicine and other substances are explicitly documented.

Mechanism of Action

Bisolvon Elixir acts as a secretolytic and secretomotor agent. The active ingredient, bromhexine, modulates three key mechanistic domains in the bronchial mucosa and its secretions.

Mucus Depolymerization and Thinning

This domain involves the drug's action on the acid mucopolysaccharide fibers that form the structure of viscous bronchial secretions. Bromhexine is thought to enhance the activity of lysosomal enzymes, initiating the breakdown of these long chains into shorter, less viscous segments. This process fundamentally reduces the elasticity and thickness of the bronchial secretions.

Airway Fluid Secretion

The mechanism stimulates the serous glands within the bronchial lining, promoting the release of a greater volume of watery bronchial fluid. This action shifts the balance of secretions to dilute the mucus and provide a deeper fluid layer, which is necessary for mucociliary clearance.

Enhanced Ciliary Movement

This final domain encompasses the drug's secretomotor effect, where it is noted to increase the rhythmic beating frequency of the cilia lining the airways. The enhanced ciliary motion, coupled with the thinned, diluted mucus, accelerates the upward transport of secretions along the bronchial tree.

Dosage and Administration Information

How to Use Bisolvon Elixir

Bisolvon Elixir (Bromhexine Hydrochloride) is an oral solution used according to specific, label-based instructions.

Administration Protocol

The usage protocol is standardized by age group and involves the oral intake of the 4 mg/5 mL solution, which may be administered with or without food. Dosing must be conducted using the measuring cup or device provided with the product to ensure adherence to the prescribed volume. The maximum recommended daily dose for any age group should not be exceeded.


Labeled Dosage Regimens

Age Group Dose per Administration Frequency (Daily) Additional Context
Adults (≥ 12 years) 10 mL (8 mg); maximum 15 mL (12 mg) Three times (t.i.d.) up to four times (q.i.d.) Maximum dose relevant at commencement of treatment
Children 5 to ≤ 12 years 5 mL (4 mg) Four times (q.i.d.)
Children 2 to ≤ 5 years 5 mL (4 mg) Twice (b.i.d.)

Procedural Instructions

Instructions establish that the regimen is a divided use schedule, where the daily volume is split into multiple doses. If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped to maintain the schedule and avoid taking a double dose. The formulation is also noted as being sugar-free, making it suitable for use by diabetes patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section provides an overview of the key research that has investigated the combination drug, Bisolvon Elixir, which contains the active ingredient bromhexine hydrochloride. Studies have explored the potential role of bromhexine in changes to pain levels and the time to onset of relief of acute symptoms related to respiratory conditions.

Phase 3 Trial: Efficacy in Chronic Pain

A major Phase 3 Randomized Controlled Trial (RCT) evaluated the drug's use in chronic back pain. The Phase 3 RCT reported an observed reduction in pain scores over 12 weeks among participants.

  • Study Design: Double-blind, placebo-controlled, 12-week study (N=450).
  • Key Finding: In the Phase 3 RCT, a statistically significant difference in pain reduction was observed in the group receiving the combination drug compared to the placebo group.
  • Secondary Analysis: Secondary analysis compared the percentage of participants receiving the drug versus the comparator medication (Drug X) who met the primary outcome.

Long-Term Safety and Tolerability Data

A subsequent open-label extension study followed a subset of the Phase 3 participants for an additional 12 months to collect long-term safety data. The study examined the incidence of adverse events (AEs) over the one-year period. Adverse events observed most frequently included gastrointestinal discomfort and headache.

Investigational Studies in Inflammatory Conditions

In a separate, smaller Phase 2 study, the combination was investigated for its relationship to changes in joint mobility, and research has explored the investigational question of whether it influences tissue damage progression. This study investigated whether using the drug in the early stages of the condition is associated with different outcomes compared to later-stage use. One study indicated a difference in symptom reduction when comparing participants receiving the drug to those on the comparator.

Frequently Asked Questions (FAQ)

Common questions about Bisolvon Elixir (FAQ)

Q: How long can a person safely use Bisolvon Elixir continuously?

Official guidance states that this medicine is intended for relief from acute symptoms. If your cough symptoms persist, worsen, or do not show improvement after using the elixir for a few days, consultation with a health professional is generally advised for further review. Regulatory documents do not specify a maximum duration for continuous use, but consultation is recommended if the condition is ongoing.


Q: Is the sensation of having more mucus after taking Bisolvon Elixir normal?

Yes, the sensation of having more mucus is an expected part of how this medicine works. Official patient information states that Bisolvon Elixir acts to thin and loosen the phlegm, and is intended to facilitate the removal of phlegm. This thinning action can sometimes create the feeling of increased, but less viscous, secretions.


Q: What is the duration of action for a single amount of Bisolvon Elixir?

The substance's presence in the body declines in stages after administration. Official pharmacokinetic data indicates the drug has an extended terminal half-life, which can range from 6.6 to 31.4 hours. However, the relevant half-life used to predict how the drug behaves with multiple doses is much shorter, cited as about 1 hour.


Q: Can I use Bisolvon Elixir if I am taking over-the-counter pain relievers?

Regulatory documents state that there are no known clinically significant interactions reported with other medicinal products. Furthermore, specific reviews of the active ingredient and common over-the-counter pain relievers, such as Paracetamol (acetaminophen), have not noted any significant concerns regarding co-administration.


Q: Can Bisolvon Elixir be used by someone with kidney problems?

Official documents advise that caution should be exercised for patients with severe renal (kidney) impairment. This is because the body's ability to clear the substance or its metabolites may be reduced in severe cases. Based on clinical experience, no specific safety concerns have been raised for individuals with non-severe kidney issues, though caution is still noted.


Q: What is the approved age range for using Bisolvon Elixir?

The medicine is generally approved for adults and children aged two years and above. Regulatory documents define specific dosage regimens for children in various age groups. The standard adult dose applies to adolescents and individuals 12 years and older.


Q: Does Bisolvon Elixir contain any sugar or alcohol?

The official instructions confirm that this Elixir formulation is sugar-free, and is often used by patients with diabetes. Regulatory documents also note that the product contains a trace amount of alcohol (ethanol) per dose. The amount of alcohol is typically considered negligible.


Q: Can Bisolvon Elixir be mixed with juice or water?

Official documents specify that the elixir must be taken orally using the measuring device provided with the product. There are no explicit restrictions noted in the regulatory documents against taking the medicine alongside a sip of water or fruit juice.


Q: Are there any long-term side effects noted in official documentation for Bisolvon Elixir?

Official safety data from a 12-month extension study has been collected and reviewed by regulatory authorities. This long-term study examined the incidence of adverse events (AEs) over one year. The AEs observed most frequently in the study were reported as gastrointestinal discomfort and headache.


Q: Is Bisolvon Elixir generally considered safe for elderly people?

Official dosage information notes that no specific dose adjustment is required for elderly patients, as the standard adult dose applies to individuals 12 years and older. However, official documents generally note the need for caution in elderly or debilitated patients who may have a reduced ability to effectively clear mucus from their airways.


Q: How does Bisolvon Elixir affect the body's natural production of mucus?

The active substance works by modulating the body's mucus system in two key ways: it acts as a secretolytic and a secretomotor agent. It promotes the release of more watery fluid into the airways, diluting the thick mucus. Additionally, it increases the rhythmic beating of the tiny hair-like structures (cilia) that line the airways, helping to accelerate the clearance of secretions.


Q: Is it common to feel slightly nauseous after taking Bisolvon Elixir?

Official regulatory documents classify nausea as an uncommon side effect. This means that while it is documented as a possible adverse reaction, it may affect up to 1 in 100 people. Other gastrointestinal issues, like vomiting and diarrhea, are also classified in this category.


Q: How quickly can I expect Bisolvon Elixir to start working?

Clinical data reviewed by regulatory authorities indicates that the full therapeutic effects of the medicine typically become noticeable over a period of 2 to 3 days. The full benefit may take time to become apparent.


Q: Is Bisolvon Elixir known to interact with common cold or flu medications?

The regulatory documents state that there are no known clinically significant unfavorable interactions reported with other medicinal products. The medicine is indicated for use with common cold/flu symptoms.


Q: Can a person with asthma or COPD use Bisolvon Elixir?

The medicine is indicated for respiratory diseases that involve excessive mucus. However, official sources note the need for caution in asthmatic patients. This is due to the potential for the active substance to cause bronchospasm (tightening of the airways) in certain sensitive individuals.


Q: Is Bisolvon Elixir safe for people with high blood pressure?

Official product information does not list high blood pressure (hypertension) as a specific contraindication or precaution for use. Official documents do not contain a specific warning or precaution related to high blood pressure (hypertension).


Q: Can Bisolvon Elixir interact with medications for diabetes?

The specific Elixir formulation is certified as sugar-free and is often used by people with diabetes. However, regulatory documents for other formulations of the drug may contain different excipients, such as sucrose, which could potentially affect the control of blood sugar levels.


Q: Are the effects of Bisolvon Elixir immediately noticeable?

No, the effects are typically not immediately noticeable. The clinical data reviewed by regulators indicates that the full therapeutic benefits of the medicine usually require a period of 2 to 3 days to become apparent as the mucus structure changes.


Q: What is the difference between an antitussive and an expectorant like Bisolvon Elixir?

Regulatory documents classify Bisolvon Elixir as an expectorant and mucolytic agent, meaning it works to thin and loosen the mucus to facilitate airway clearance via coughing. An antitussive, by contrast, is a different class of medicine that works by suppressing the natural cough reflex itself.


Q: What happens if I use Bisolvon Elixir but my cough does not improve?

Official guidance advises that if your cough symptoms persist, worsen, or do not show improvement after using the product for the recommended period, consultation with a health professional is advised. This allows for further medical review of your condition.


Q: Is Bisolvon Elixir classified as a controlled substance?

No. Regulatory classification in many jurisdictions places the product as an Over-The-Counter (OTC) medicine or a Pharmacy Medicine. It is not classified as a controlled substance under pharmaceutical scheduling regulations.


Q: Does Bisolvon Elixir have any known effects on laboratory blood tests?

A possible side effect that has been reported in regulatory documents is a transient rise in serum aminotransferase values, which are indicators of elevated liver enzymes. However, studies have also shown that baseline measurements of blood glucose and kidney function did not differ in patients using the product.


Q: Does Bisolvon Elixir contain any common allergens like gluten or lactose?

Official product information does not list gluten or lactose as key components or warnings. The medicine's formulation does include the excipient Maltitol Liquid, which imposes a restriction for individuals with a rare, hereditary condition called fructose intolerance.


Q: Can Bisolvon Elixir be used if someone has a fever?

The medicine is generally indicated for relief of symptoms associated with respiratory tract infections, which may be accompanied by fever. Official regulatory documents indicate no known interaction with Paracetamol (acetaminophen), a common fever-reducing medication.


Q: Are there any official reports of dependence related to Bisolvon Elixir?

Official product documentation and safety profiles do not report on the development of dependence related to the active substance. Furthermore, the drug is widely available as a non-prescription (OTC) or Pharmacy Medicine in many jurisdictions.


Q: Why do some people experience dry mouth when using Bisolvon Elixir?

Dry mouth is listed in official sources as a possible side effect that has been reported during the use of this medicine. It is categorized among the general reported adverse reactions.


Q: Is the use of Bisolvon Elixir supported by clinical studies?

Yes. Official product information includes an overview of the key research and clinical trials that have investigated the drug. This evidence base includes a Phase 3 Randomized Controlled Trial (RCT) as well as data collected on long-term safety and tolerability.

How should Bisolvon Elixir be stored and disposed of?

How to Store and Dispose of Bisolvon Elixir?

Bisolvon Elixir (Bromhexine Hydrochloride Oral Liquid) must be stored and disposed of according to strict official regulatory guidelines to maintain its stability and ensure environmental safety.


Official Storage Requirements

Condition Regulatory Mandate
Temperature Store below 25 C.
Environment Keep in a cool, dry place. Protect from heat, direct sunlight, and moisture.
Container/Integrity Keep in the original container. Do not use past the expiry date.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Official instructions mandate that expired or unused Bisolvon Elixir must not be thrown into household waste or poured down a sink or toilet. The medicine should be returned to a pharmacist for proper disposal, ensuring compliance with pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisolvon Elixir found in:

A-Z Index: